Neuronetics Appoints a New Chief Financial Officer
Neuronetics, Inc. (NASDAQ: STIM), a dynamic leader in medical technology focused on mental health innovations, has announced the appointment of Steven Pfanstiel as its new Chief Financial Officer. This appointment marks a pivotal change as the company continues to transform patient care through cutting-edge solutions.
Transition in Leadership
Steven Pfanstiel brings with him over two decades of invaluable experience in the healthcare sector. He takes over from Steve Furlong, who has played a significant role as CFO in navigating challenging market environments and steering the company through its recent acquisitions. Furlong will continue in his capacity as Senior Advisor to the CEO through March 2026, ensuring a seamless transition.
Legacy of Leadership
Keith J. Sullivan, the President and Chief Executive Officer of Neuronetics, has expressed gratitude for Furlong's leadership, highlighting his significant contributions over the past six years. Sullivan is confident that Pfanstiel will propel the company forward in its mission to expand access to mental health treatments and foster sustainable growth.
Proven Track Record of Success
Prior to joining Neuronetics, Pfanstiel served as CFO and COO at Marinus Pharmaceuticals, where he played a crucial role in launching their flagship product. His experience includes leadership roles at other prominent healthcare companies such as Lifescan and Optinose, and earlier career positions at Johnson & Johnson, where he gained extensive knowledge across various product lines, including pharmaceuticals and orthopedics.
Vision for the Future
Pfanstiel expressed his enthusiasm about joining Neuronetics at a transformative time. He acknowledged the company's strong foothold in providing care to patients struggling with mental health disorders. The unique combination of NeuroStar TMS technology and Greenbrook's clinic network presents significant growth opportunities within this critical segment of healthcare.
Strategic Guidance Reaffirmed
Alongside the leadership transition, Neuronetics is reaffirming its guidance for the upcoming quarters, anticipating a positive cash flow and solid operational performance. This outlook is bolstered by the successful integration of Greenbrook's operations and ongoing advancements in key growth areas.
About Neuronetics
Neuronetics, Inc. champions mental health by providing innovative treatment options that prioritize patient care. The company's offerings include NeuroStar Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD), which utilizes a unique TMS technology. It is recognized as the leading treatment for MDD in adults and has a robust clinical data backing its efficacy. Neuronetics also operates a network of Greenbrook TMS clinics across the country, enhancing access to comprehensive mental health solutions.
Commitment to Mental Health
As a pioneering force in neuroscience, Neuronetics remains dedicated to advancing mental healthcare. Their commitment is underscored by their substantial treatment reach and growing patient outcomes, having delivered millions of therapy sessions to individuals facing depression and other mental health challenges. This mission is not only vital for the patients but also positions Neuronetics for continued growth in a rapidly evolving healthcare landscape.
Frequently Asked Questions
Who is the new CFO of Neuronetics?
The new CFO of Neuronetics is Steven Pfanstiel, who has extensive experience in healthcare finance.
What role did Steve Furlong play at Neuronetics?
Steve Furlong served as CFO for six years and will now transition to a Senior Advisor role.
What product is Neuronetics known for?
Neuronetics is known for the NeuroStar Advanced Therapy, a leading TMS treatment for major depressive disorder.
What is the outlook for Neuronetics?
Neuronetics has reaffirmed its positive outlook, anticipating significant performance improvements and positive cash flow.
How many treatments has NeuroStar delivered?
NeuroStar has delivered over 7.4 million treatments to patients suffering from depression.
